Predictive Outcomes for HER2-enriched Cancer Using Growth and Metastasis Signatures Driven By SPARC

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Metastatic dissemination is a critical factor in breast cancer progression and patient outcomes.
• The role of the matricellular glycoprotein secreted protein acidic and rich in cysteine (SPARC) in breast cancer aggressiveness is established, but its underlying mechanisms remain unclear.

Purpose of the Study:

• To elucidate the mechanisms by which SPARC contributes to primary tumor growth and metastatic dissemination in breast cancer.
• To investigate SPARC's downstream effectors and their potential as therapeutic targets for antimetastatic strategies.

Main Methods:

• Utilized shRNA to knock down SPARC expression in murine breast cancer models (4T1 and LM3 cells in BALB/c mice).
• Performed global transcriptomic analysis to identify SPARC-regulated pathways.
• Conducted biological validations to confirm findings, including assessment of cell cycle, myeloid-derived suppressor cells (MDSC) expansion, and cell adhesion.

Main Results:

• SPARC knockdown significantly reduced primary tumor growth and completely inhibited lung metastasis.
• SPARC promotes tumor growth via enhanced cell cycle and COX-2-mediated expansion of MDSC.
• SPARC facilitates metastasis through COX-2-independent enhancement of tumor cell disengagement and lung adherence.
• SPARC-induced gene expression signatures correlated with clinical outcomes in HER2-enriched breast cancer patients.

Conclusions:

• SPARC plays a significant prometastatic role in breast cancer, influencing both primary tumor growth and metastatic dissemination.
• SPARC and its downstream pathways, including COX-2 and MDSC expansion, are potential therapeutic targets for combating breast cancer metastasis.
• SPARC-driven gene expression profiles may serve as predictive biomarkers for patient outcomes in specific breast cancer subtypes.